Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries
IntroductionAbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was an observational study of patients with rheumatoid arthritis who initiated intravenous abatacept in clinical practice. We aimed to compare abatacept retention rates and clinical outcomes in patients from Germany versus othe...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
12 July 2019
|
| In: |
Clinical rheumatology
Year: 2019, Jahrgang: 38, Heft: 11, Pages: 3049-3059 |
| ISSN: | 1434-9949 |
| DOI: | 10.1007/s10067-019-04648-5 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1007/s10067-019-04648-5
|
| Verfasserangaben: | Rieke Alten, Eugen Feist, Hanns-Martin Lorenz, Hubert Nüßlein, Reinhard E. Voll, Melanie Chartier, Yedid Elbez, Christiane Rauch |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1684398088 | ||
| 003 | DE-627 | ||
| 005 | 20241221032347.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191205s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-019-04648-5 |2 doi | |
| 035 | |a (DE-627)1684398088 | ||
| 035 | |a (DE-599)KXP1684398088 | ||
| 035 | |a (OCoLC)1341280348 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Alten, Rieke |e VerfasserIn |0 (DE-588)111167019 |0 (DE-627)502213248 |0 (DE-576)289694353 |4 aut | |
| 245 | 1 | 0 | |a Abatacept retention and clinical outcomes in rheumatoid arthritis |b real-world data from the German cohort of the ACTION study and a comparison with other participating countries |c Rieke Alten, Eugen Feist, Hanns-Martin Lorenz, Hubert Nüßlein, Reinhard E. Voll, Melanie Chartier, Yedid Elbez, Christiane Rauch |
| 264 | 1 | |c 12 July 2019 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.12.2019 | ||
| 520 | |a IntroductionAbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was an observational study of patients with rheumatoid arthritis who initiated intravenous abatacept in clinical practice. We aimed to compare abatacept retention rates and clinical outcomes in patients from Germany versus other countries.MethodBaseline characteristics, crude retention rates, and clinical outcomes were compared by treatment line in the German cohort at 2 years. In addition, biologic-naïve patients were compared with biologic-naïve patients pooled from other participating countries.ResultsIn the German cohort, 677/680 (99.6%) patients enrolled were evaluable and 171/677 (25.3%) were biologic naïve. At baseline, abatacept monotherapy was received by a similar proportion of biologic-naïve and biologic-failure patients in the German cohort, but by a greater proportion of biologic-naïve patients in German versus other countries cohort (27.5 vs. 12.9%). The overall crude abatacept retention rate at 2 years in the German cohort was 39.9%; retention rate did not differ significantly by treatment line, but among biologic-naïve patients it was lower in Germany than in the other countries cohort (42.1 vs. 58.7%; log-rank test p < 0.001). At 2 years, good/moderate European League Against Rheumatism (EULAR) response rates in biologic-naïve patients were 85.5% in the German and 92.1% in other countries cohort (p = 0.163).ConclusionsIn the German cohort of ACTION, abatacept retention at 2 years was similar in biologic-naïve and biologic-failure patients. Biologic-naïve patients in German cohort had a significantly lower abatacept retention rate and a trend of lower good/moderate EULAR response rate than those in the other countries cohort.Key Points • Analyses of data from national patient cohorts provide insight on local treatment patterns. • In the German cohort of the ACTION study, abatacept retention at 2 years was similar in biologic-naïve and biologic-failure patients. • Biologic-naïve patients from the German cohort had a significantly lower abatacept retention rate and a trend of lower good/moderate EULAR response rate than patients from other countries. • Data from large international studies may not be directly applicable to individual countries. | ||
| 650 | 4 | |a Biologic-failure patients | |
| 650 | 4 | |a Biologic-naïve patients | |
| 650 | 4 | |a Clinical practice | |
| 650 | 4 | |a Germany | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 700 | 1 | |8 1\p |a Feist, Eugen |d 1969- |e VerfasserIn |0 (DE-588)118138847 |0 (DE-627)07926655X |0 (DE-576)29173524X |4 aut | |
| 700 | 1 | |a Lorenz, Hanns-Martin |d 1962- |e VerfasserIn |0 (DE-588)112253865 |0 (DE-627)627277845 |0 (DE-576)167601369 |4 aut | |
| 700 | 1 | |8 2\p |a Nüßlein, Hubert G. |e VerfasserIn |0 (DE-588)1096211130 |0 (DE-627)856608270 |0 (DE-576)467921121 |4 aut | |
| 700 | 1 | |8 3\p |a Voll, Reinhard |d 1964- |e VerfasserIn |0 (DE-588)114075581 |0 (DE-627)691206287 |0 (DE-576)289785006 |4 aut | |
| 700 | 1 | |a Chartier, Melanie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Elbez, Yedid |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rauch, Christiane |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d London : Springer, 1982 |g 38(2019), 11, Seite 3049-3059 |h Online-Ressource |w (DE-627)27159909X |w (DE-600)1480901-1 |w (DE-576)088704351 |x 1434-9949 |7 nnas |a Abatacept retention and clinical outcomes in rheumatoid arthritis real-world data from the German cohort of the ACTION study and a comparison with other participating countries |
| 773 | 1 | 8 | |g volume:38 |g year:2019 |g number:11 |g pages:3049-3059 |g extent:11 |a Abatacept retention and clinical outcomes in rheumatoid arthritis real-world data from the German cohort of the ACTION study and a comparison with other participating countries |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10067-019-04648-5 |x Verlag |x Resolving-System |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 3\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20191205 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 112253865 |a Lorenz, Hanns-Martin |m 112253865:Lorenz, Hanns-Martin |d 910000 |d 910100 |e 910000PL112253865 |e 910100PL112253865 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 999 | |a KXP-PPN1684398088 |e 3556901064 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Rieke Alten, Eugen Feist, Hanns-Martin Lorenz, Hubert Nüßlein, Reinhard E. Voll, Melanie Chartier, Yedid Elbez, Christiane Rauch"]},"recId":"1684398088","note":["Gesehen am 05.12.2019"],"id":{"eki":["1684398088"],"doi":["10.1007/s10067-019-04648-5"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"12 July 2019"}],"physDesc":[{"extent":"11 S."}],"person":[{"given":"Rieke","display":"Alten, Rieke","family":"Alten","role":"aut"},{"role":"aut","given":"Eugen","family":"Feist","display":"Feist, Eugen"},{"role":"aut","display":"Lorenz, Hanns-Martin","family":"Lorenz","given":"Hanns-Martin"},{"given":"Hubert G.","family":"Nüßlein","display":"Nüßlein, Hubert G.","role":"aut"},{"given":"Reinhard","display":"Voll, Reinhard","family":"Voll","role":"aut"},{"role":"aut","display":"Chartier, Melanie","family":"Chartier","given":"Melanie"},{"display":"Elbez, Yedid","family":"Elbez","given":"Yedid","role":"aut"},{"role":"aut","given":"Christiane","display":"Rauch, Christiane","family":"Rauch"}],"title":[{"title_sort":"Abatacept retention and clinical outcomes in rheumatoid arthritis","subtitle":"real-world data from the German cohort of the ACTION study and a comparison with other participating countries","title":"Abatacept retention and clinical outcomes in rheumatoid arthritis"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Clinical rheumatology","title":"Clinical rheumatology"}],"part":{"pages":"3049-3059","text":"38(2019), 11, Seite 3049-3059","volume":"38","issue":"11","year":"2019","extent":"11"},"language":["eng"],"id":{"zdb":["1480901-1"],"issn":["1434-9949"],"eki":["27159909X"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"1982","publisher":"Springer ; Springer","dateIssuedDisp":"1982-","publisherPlace":"London ; [Berlin ; Heidelberg]"}],"pubHistory":["1.1982 -"],"recId":"27159909X","note":["Gesehen am 05.12.05"],"disp":"Abatacept retention and clinical outcomes in rheumatoid arthritis real-world data from the German cohort of the ACTION study and a comparison with other participating countriesClinical rheumatology"}]} | ||
| SRT | |a ALTENRIEKEABATACEPTR1220 | ||